Synlogic (NASDAQ: SYBX) reported Q4 EPS of ($0.47), $0.07 better than the analyst estimate of ($0.54). Revenue for the quarter came in at $111 thousand versus the consensus estimate of $210 thousand.

“2019 is an exciting year for Synlogic as we continue to advance out platform and programs,” said Aoife Brennan, M.B., Ch.B. Synlogic’s president and chief executive officer. “Data expected mid-year from clinical trials of SYNB1020 and SYNB1618, in patients with hyperammonemia and phenylketonuria, respectively, will guide our plans for future development of our Synthetic Biotic medicines in these areas and additional rare metabolic diseases. We are also exploring new applications of our platform as we advance our first immuno-oncology program toward submission of an Investigational New Drug (IND) application and into clinical studies. Furthermore, with our increased capability to manufacture clinical trial material, we are now in a position to advance our programs through development as expeditiously as possible.”

For earnings history and earnings-related data on Synlogic (SYBX) click here.